LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment
AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast cancer. Over the last week, AstraZeneca's share price increased by 1%, aligning closely with the broader market's growth of 2%. While the company's recent product developments, including trials for ENHERTU and IMFINZI, and collaborations like the partnership with Danaher Corporation, underscore its...